Marie O’Farrell

1.3k total citations · 3 hit papers
25 papers, 901 citations indexed

About

Marie O’Farrell is a scholar working on Cancer Research, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Marie O’Farrell has authored 25 papers receiving a total of 901 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Cancer Research, 13 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Marie O’Farrell's work include Cancer, Lipids, and Metabolism (14 papers), Cancer, Hypoxia, and Metabolism (10 papers) and Lung Cancer Treatments and Mutations (5 papers). Marie O’Farrell is often cited by papers focused on Cancer, Lipids, and Metabolism (14 papers), Cancer, Hypoxia, and Metabolism (10 papers) and Lung Cancer Treatments and Mutations (5 papers). Marie O’Farrell collaborates with scholars based in United States, United Kingdom and France. Marie O’Farrell's co-authors include George Kemble, William McCulloch, Douglas Buckley, Katharine Grimmer, Gregory Duke, Allan S. Wagman, Timothy S. Heuer, Gerald S. Falchook, Andrew Brenner and Emma Dean and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

Marie O’Farrell

25 papers receiving 889 citations

Hit Papers

First-in-human study of the safety, pharmacokinetics, and... 2021 2026 2022 2024 2021 2021 2024 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors
    2021 192 citations Gerald S. Falchook, Jeffrey R. Infante et al. EClinicalMedicine profile →
  2. TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial
    2021 163 citations Rohit Loomba, Rizwana Mohseni et al. Gastroenterology profile →
  3. Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial
    2024 44 citations Rohit Loomba, Pierre Bédossa et al. ˜The œLancet. Gastroenterology & hepatology profile →

Peers

Marie O’Farrell
Angélique Gougèlet France
Quentin Bayard France
Chiara Busletta Italy
Zeribe C. Nwosu United States
Tomohiko Sakabe Japan
Nicolas Dif France
Emma Du United States
Da Wang China
Betty L. Cabrera United States
Jian Kong China
Angélique Gougèlet France
Marie O’Farrell
Citations per year, relative to Marie O’Farrell Marie O’Farrell (= 1×) peers Angélique Gougèlet

Countries citing papers authored by Marie O’Farrell

Since Specialization
Citations

This map shows the geographic impact of Marie O’Farrell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marie O’Farrell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marie O’Farrell more than expected).

Fields of papers citing papers by Marie O’Farrell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marie O’Farrell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marie O’Farrell. The network helps show where Marie O’Farrell may publish in the future.

Co-authorship network of co-authors of Marie O’Farrell

This figure shows the co-authorship network connecting the top 25 collaborators of Marie O’Farrell. A scholar is included among the top collaborators of Marie O’Farrell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marie O’Farrell. Marie O’Farrell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Loomba, Rohit, Pierre Bédossa, Katharine Grimmer, et al.. (2024). Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial. ˜The œLancet. Gastroenterology & hepatology. 9(12). 1090–1100. 44 indexed citations breakdown →
2.
O’Farrell, Marie, G M Duke, R. Webster Crowley, et al.. (2022). FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models. Scientific Reports. 12(1). 15661–15661. 66 indexed citations
3.
Falchook, Gerald S., Jeffrey R. Infante, Hendrik‐Tobias Arkenau, et al.. (2021). First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. EClinicalMedicine. 34. 100797–100797. 192 indexed citations breakdown →
4.
Loomba, Rohit, Rizwana Mohseni, Kathryn Jean Lucas, et al.. (2021). TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology. 161(5). 1475–1486. 163 indexed citations breakdown →
5.
6.
Aggarwal, Rahul, Wassim Abida, Michael T. Schweizer, et al.. (2019). Abstract CT095: A Phase Ib/IIa study of the BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). Cancer Research. 79(13_Supplement). CT095–CT095. 6 indexed citations
7.
Buckley, Douglas, Gregory Duke, Timothy S. Heuer, et al.. (2017). Fatty acid synthase – Modern tumor cell biology insights into a classical oncology target. Pharmacology & Therapeutics. 177. 23–31. 151 indexed citations
8.
Dean, Emma, Gerald S. Falchook, Manish R. Patel, et al.. (2016). Preliminary activity in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640.. Journal of Clinical Oncology. 34(15_suppl). 2512–2512. 38 indexed citations
9.
O’Farrell, Marie, et al.. (2016). Abstract A75: Translational studies of a first-in-class FASN Inhibitor, TVB-2640, linking preclinical studies to clinical laboratory observations in solid tumor patients. Molecular Cancer Research. 14(1_Supplement). A75–A75. 3 indexed citations
10.
O’Farrell, Marie, R. Webster Crowley, Timothy S. Heuer, et al.. (2015). Abstract 2675: Biomarker and PK/PD analyses of first in class FASN inhibitor TVB-2640 in a first-in-human phase 1 study in solid tumor patients. Cancer Research. 75(15_Supplement). 2675–2675. 2 indexed citations
11.
O’Farrell, Marie, R. Webster Crowley, Timothy S. Heuer, et al.. (2015). Abstract B13: Biomarker Analyses from Dose Escalation Phase of FASN Inhibitor TVB-2640 Phase 1 Study Shows Target Engagement in Solid Tumor Patients. Molecular Cancer Therapeutics. 14(12_Supplement_2). B13–B13. 1 indexed citations
12.
Voskoboynik, Mark, Jon Infante, Andrew Brenner, et al.. (2015). 27LBA Evidence of activity of a new mechanism of action (MoA): A first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640, as monotherapy or in combination. European Journal of Cancer. 51. S724–S724. 5 indexed citations
13.
Brenner, Andrew, Jeffrey R. Infante, Manish R. Patel, et al.. (2015). Abstract A54: First-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640 as monotherapy or in combination - final results of dose escalation. Molecular Cancer Therapeutics. 14(12_Supplement_2). A54–A54. 6 indexed citations
14.
Rewcastle, Gordon W., Jack U. Flanagan, Swarna A. Gamage, et al.. (2014). Abstract 1644: Design and discovery of PWT33597 (VDC-597), a dual inhibitor of PI3-kinase alpha and mTOR. Cancer Research. 74(19_Supplement). 1644–1644. 4 indexed citations
15.
Chow, Hoi Yee, Adrian M. Jubb, Zahara M. Jaffer, et al.. (2012). p21-Activated Kinase 1 Is Required for Efficient Tumor Formation and Progression in a Ras-Mediated Skin Cancer Model. Cancer Research. 72(22). 5966–5975. 101 indexed citations
16.
O’Farrell, Marie, Richard Ventura, Albert Tai, & David J. Matthews. (2012). Abstract 3737: The PI3K/mTOR inhibitor PWT33597 regresses 786-0 renal xenografts. Cancer Research. 72(8_Supplement). 3737–3737. 2 indexed citations
17.
18.
Matthews, David J., et al.. (2012). Discovery of PI3K delta inhibitors for the treatment of inflammatory and autoimmune disease. 3. 1 indexed citations
19.
Matthews, David J., et al.. (2011). Abstract 4485: Preclinical characterization of PWT33597, a dual inhibitor of PI3-kinase alpha and mTOR. Cancer Research. 71(8_Supplement). 4485–4485. 4 indexed citations
20.
Matthews, David J., et al.. (2011). Abstract B160: PWT33597 promotes apoptosis in tumor cells through balanced dual inhibition of PI3K alpha and mTOR.. Molecular Cancer Therapeutics. 10(11_Supplement). B160–B160. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Angélique Gougèlet Breakdown of academic impact, for papers by Quentin Bayard Breakdown of academic impact, for papers by Chiara Busletta Breakdown of academic impact, for papers by Zeribe C. Nwosu Breakdown of academic impact, for papers by Tomohiko Sakabe Breakdown of academic impact, for papers by Nicolas Dif Breakdown of academic impact, for papers by Emma Du Breakdown of academic impact, for papers by Da Wang Breakdown of academic impact, for papers by Betty L. Cabrera Breakdown of academic impact, for papers by Jian Kong
Rankless by CCL
2026